Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMTX

Immatics N.V

Dec 26 • 03:23PM ET

7.04

Dollar change -0.06
Percentage change -0.85	%

Healthcare • Biotechnology • Germany • NASD

Peers: MRNA BNTX ALLO CLLS BLUE ADAP FATE PSTX GOSS TIL

| Held by: SPDW KOMP ONEQ GWX GINN CNCR BBC SMLV CHNA BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	25.46%	Shs Outstand	103.11M	Perf Week	4.61%
Market Cap	840.27M	Forward P/E	-	EPS next Y	-1.19	Insider Trans	0.00%	Shs Float	88.97M	Perf Month	-7.25%
Income	-60.25M	PEG	-	EPS next Q	-0.29	Inst Own	61.69%	Short Float	9.51%	Perf Quarter	-39.98%
Sales	125.71M	P/S	6.68	EPS this Y	46.61%	Inst Trans	-3.52%	Short Ratio	13.71	Perf Half Y	-40.29%
Book/sh	4.14	P/B	1.70	EPS next Y	-78.10%	ROA	-10.88%	Short Interest	8.46M	Perf Year	-32.89%
Cash/sh	4.59	P/C	1.53	EPS next 5Y	-	ROE	-17.48%	52W Range	6.68 - 13.77	Perf YTD	-33.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.16%	ROI	-13.64%	52W High	-48.87%	Beta	0.75
Dividend TTM	-	Quick Ratio	3.98	Sales past 5Y	145.27%	Gross Margin	-	52W Low	5.39%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	3.98	EPS Y/Y TTM	-233.52%	Oper. Margin	-57.69%	RSI (14)	34.46	Volatility	5.38% 4.53%
Employees	343	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-47.93%	Recom	1.00	Target Price	16.68
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	73.58%	Payout	-	Rel Volume	0.41	Prev Close	7.10
Sales Surprise	235.50%	EPS Surprise	52.32%	Sales Q/Q	761.57%	Earnings	Nov 18 BMO	Avg Volume	616.97K	Price	7.04
SMA20	-5.95%	SMA50	-15.26%	SMA200	-34.04%	Trades		Volume	229,567	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	Piper Sandler	Overweight	$19
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Mar-31-23	Initiated	Mizuho	Buy	$12
Mar-24-23	Initiated	Bryan Garnier	Buy	$16
Nov-20-20	Initiated	BofA Securities	Buy	$13
Sep-22-20	Initiated	Goldman	Buy	$17
Jul-27-20	Initiated	SVB Leerink	Outperform	$17
Jul-24-20	Initiated	Jefferies	Buy

Nov-19-24 07:25AM	Immatics Sees Revenue Surge Despite R&D Expenses (TipRanks)
Nov-18-24 07:00AM	Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER IMA402 Targeting PRAME (GlobeNewswire)
Nov-08-24 05:00PM	Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME (GlobeNewswire)
Oct-11-24 06:57AM	Immatics Advances IMA203 to Phase 3 Trial in Melanoma (TipRanks)
Oct-10-24 08:50PM	Immatics Announces Pricing of $150 Million Public Offering (GlobeNewswire) -15.58%
07:30AM	Loading…
07:30AM	Immatics Announces Proposed $150 Million Public Offering (GlobeNewswire)
06:30AM	Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial (GlobeNewswire)
Oct-09-24 08:03AM	Immatics N.V. (IMTX) Receives Buy Rating from Analysts (Insider Monkey)
Oct-04-24 09:00AM	Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 (GlobeNewswire)
Sep-16-24 05:25AM	Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update (GlobeNewswire)
Sep-06-24 07:00AM	Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 (GlobeNewswire)
Aug-13-24 07:00AM	Immatics Announces Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Immatics Appoints Alise Reicin to Board of Directors (GlobeNewswire)
Jul-18-24 09:00AM	Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
08:15AM	Loading…
May-14-24 08:15AM	Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.45%
07:00AM	Immatics Announces First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Mar-21-24 02:52PM	IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -5.89%
07:00AM	Immatics Announces Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Jan-17-24 08:30PM	Immatics Announces Pricing of $175 Million Public Offering (GlobeNewswire) -7.36%
04:01PM	Immatics Announces Proposed Public Offering (GlobeNewswire)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire)
Nov-14-23 07:00AM	Immatics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-08-23 07:00AM	Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial (GlobeNewswire)
Oct-24-23 07:00AM	Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy (GlobeNewswire)
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-11-23 07:00AM	Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics (ACCESSWIRE)
Aug-17-23 07:00AM	Immatics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
07:00AM	Loading…
Aug-10-23 07:00AM	Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors (GlobeNewswire)
Jul-24-23 07:00AM	Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb (GlobeNewswire)
May-16-23 07:00AM	Immatics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 07:00AM	Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME (GlobeNewswire) +27.46%
May-01-23 07:00AM	Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration (GlobeNewswire)
Apr-23-23 08:56AM	TipRanks Perfect 10 List: These 2 Top-Rated Stocks Could Be Long-Term Winners (TipRanks)
Mar-21-23 07:31AM	Immatics Announces Full Year 2022 Financial Results and Corporate Update (GlobeNewswire)
Nov-17-22 07:00AM	Immatics Announces Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-10-22 07:37AM	Immatics Announces $110 Million Underwritten Offering of Ordinary Shares (GlobeNewswire) +11.60%
07:36AM	Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME (GlobeNewswire)
Sep-10-22 03:06AM	Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Aug-23-22 07:00AM	Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME (GlobeNewswire)
Aug-09-22 07:00AM	Immatics Announces Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jun-25-22 10:42AM	Do Its Financials Have Any Role To Play In Driving Immatics N.V.'s (NASDAQ:IMTX) Stock Up Recently? (Simply Wall St.)
Jun-07-22 07:00AM	Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer (GlobeNewswire)
Jun-02-22 07:05AM	Immatics Announces First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
06:59AM	Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs (GlobeNewswire)
May-26-22 06:54AM	What Kind Of Shareholders Own Immatics N.V. (NASDAQ:IMTX)? (Simply Wall St.)
May-18-22 07:00AM	Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
May-10-22 07:00AM	Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors (GlobeNewswire)
May-03-22 11:41AM	Immatics (NASDAQ:IMTX) shareholders have endured a 37% loss from investing in the stock a year ago (Simply Wall St.)
Apr-15-22 09:55AM	Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High? (Zacks)
Mar-31-22 12:13PM	Analysts Are Optimistic We'll See A Profit From Immatics N.V. (NASDAQ:IMTX) (Simply Wall St.)
Mar-23-22 07:00AM	Immatics Announces Full Year 2021 Financial Results and Corporate Update (GlobeNewswire)
Feb-14-22 09:54AM	Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation (Simply Wall St.)
Dec-16-21 04:42AM	News Flash: Analysts Just Made A Substantial Upgrade To Their Immatics N.V. (NASDAQ:IMTX) Forecasts (Simply Wall St.)
Dec-14-21 06:59AM	Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics TCR Bispecific Program IMA401 (GlobeNewswire) +8.88%
Nov-18-21 08:01AM	Is Immatics N.V. (NASDAQ:IMTX) Popular Amongst Institutions? (Simply Wall St.)
Nov-16-21 07:00AM	Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME (GlobeNewswire) -13.92%
Nov-01-21 08:00AM	Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancers 36th Annual Meeting (GlobeNewswire)
02:34AM	Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar? (Zacks)
Aug-20-21 07:31AM	Investors in Immatics (NASDAQ:IMTX) have made a return of 18% over the past year (Simply Wall St.)
Aug-10-21 07:00AM	Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-07-21 03:00AM	BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions (PR Newswire)
May-26-21 07:00AM	Immatics Announces Changes to its Board of Directors (GlobeNewswire)
May-22-21 04:29AM	Immatics N.V. (NASDAQ:IMTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
May-18-21 07:00AM	Immatics Announces First Quarter 2021 Financial Results and Business Update (GlobeNewswire)
May-11-21 07:00AM	Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME (GlobeNewswire)
Apr-03-21 05:41AM	What Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)? (Simply Wall St.)
Mar-30-21 07:00AM	Immatics Announces Full Year 2020 Financial Results and Corporate Update (GlobeNewswire)
Mar-17-21 07:00AM	Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs (GlobeNewswire) +25.54%
Mar-02-21 03:00AM	Callaway Golf Announces Chrome Soft X LS Golf Ball (PR Newswire)
Dec-18-20 04:30PM	Is IMTX A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)
Dec-02-20 07:00AM	Immatics Announces Third Quarter 2020 Financial Results and Business Update (GlobeNewswire)
Nov-10-20 07:00AM	Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference (GlobeNewswire)
Oct-29-20 07:00AM	Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8 (GlobeNewswire)
Oct-14-20 06:19PM	Defiance ETFs launches the first SPAC ETF (Yahoo Finance Video)
Oct-05-20 11:23AM	What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)? (Simply Wall St.)
Sep-30-20 10:01AM	Goldman Sachs Predicts Over 40% Rally for These 3 Stocks (TipRanks)
Sep-29-20 07:00AM	Immatics Appoints Arnd Christ as Chief Financial Officer (GlobeNewswire) +7.43%
Sep-15-20 07:00AM	Immatics Appoints Biotech Executive Eliot Forster to Board of Directors (GlobeNewswire)
Sep-10-20 07:00AM	Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment (GlobeNewswire)
Sep-03-20 07:00AM	Immatics Announces Second Quarter 2020 Financial Results and Business Update (GlobeNewswire)
Aug-18-20 07:00AM	Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs (GlobeNewswire)
Aug-06-20 07:00AM	Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth (GlobeNewswire)
Jul-09-20 07:00AM	Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ (GlobeNewswire)
Jul-02-20 07:00AM	Immatics Announces Completion of Business Combination and Listing on NASDAQ (GlobeNewswire)

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMTX

Immatics N.V

Upgrade your FINVIZ experience